Form 4 for MLYS Mineralys Therapeutics, Inc.
Accepted 2023-11-14 00:00:00 ET · period of report 2023-11-13 · accession 0001933414-23-000091 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-11-14 | 2023-11-13 | MLYS | Rodman David Malcom | Chief Medical Off | M - OptEx | $0.54 | +5,017 | 15.1K | +50% | +$2,709 |
| D | 2023-11-14 | 2023-11-13 | MLYS | Rodman David Malcom | Chief Medical Off | M - OptEx | $0.00 | -5,017 | 70.2K | -7% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-13 | M | A | 5,017 | $0.54 | 15,051 | D | — | — | |
| 2 | Derivative | Stock Option | 2023-11-13 | M | D | 5,017 | $0.00 | 70,242 | D | $0.54 · — to 2031-03-11 | 5,017 Common Stock | (F1) Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023. (F2) The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. |